How I treat refractory chronic graft-versus-host disease
Authors:
- 14 March 2019
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 133 (11) , 1191-1200
Abstract
Approximately 35% to 50% of patients otherwise cured of hematologic malignancies after allogeneic hematopoietic stem cell transplantation will develop the pleomorphic autoimmune-like syndrome known as chronic graft-versus-host disease (cGVHD). Since in 2005, National Institutes of Health (NIH) consensus panels have proposed definitions and classifications of disease to standardize treatment trials. Recently, the first agent was approved by the US Food and Drug Administration for steroid-refractory cGVHD. Despite these advances, most individuals do not achieve durable resolution of disease activity with initial treatment. Moreover, standardized recommendations on how to best implement existing and novel immunomodulatory agents and taper salvage agents are often lacking. Given the potential life-threatening nature of cGVHD, we employ in our practice patient assessment templates at each clinic visit to elucidate known prognostic indicators and red flags. We find NIH scoring templates practical for ongoing assessments of these complex patient cases and determination of when changes in immunosuppressive therapy are warranted. Patients not eligible or suitable for clinical trials have systemic and organ-directed adjunctive treatments crafted in a multidisciplinary clinic. Herein, we review these treatment options and offer a management and monitoring scaffold for representative patients with cGVHD not responding to initial therapy.Keywords
This publication has 105 references indexed in Scilit:
- Isomorphic Sclerotic-Type Cutaneous Chronic Graft-Versus-Host Disease: Report and Review of Chronic Graft-Versus-Host Disease in a Cutaneous Immunocompromised DistrictDermatology and Therapy, 2013
- Safety and efficacy of rituximab in steroid-refractory chronic GVHDBone Marrow Transplantation, 2012
- The Impact of Geographic Proximity to Transplant Center on Outcomes after Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2012
- Diagnosis and Treatment of Ocular Chronic Graft-Versus-Host Disease: Report From the German–Austrian–Swiss Consensus Conference on Clinical Practice in Chronic GVHDCornea, 2012
- Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective studyLeukemia, 2011
- Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysisBlood, 2011
- Evaluation of NIH consensus criteria for classification of late acute and chronic GVHDBlood, 2009
- Therapy with mycophenolate mofetil for refractory acute and chronic GVHDBone Marrow Transplantation, 2009
- Oral Candida infection and colonization in solid organ transplant recipientsOral Microbiology and Immunology, 2009
- The US FDA ‘Black Box’ Warning for Topical Calcineurin InhibitorsDrug Safety, 2008